Mariko Taga is an Assistant Professor in the Neurology Department, at the Taub Institute, and the Center for Translational and Computational Neuroimmunology. Her current research focuses on identifying specific cell subpopulations expressed in the AD pathology microenvironment, especially within neuritic plaques, using cutting-edge techniques such as Spatial Transcriptomics and multiplexed immunohistochemistry.

Ignacio graduated in Biotechnology in 2019 and completed a master’s degree in Computational Biology in 2020 (Technical University of Madrid). During this time, he joined projects to develop classification algorithms for medical data (Centre for Biomedical Technology, undergraduate student), evaluate the effects of pathogens on wild plant populations (Centre for Plant Biotechnology and Genomics, undergraduate student), and model how diseases spread in plants (Department of Applied Mathematics, Technical University of Madrid, graduate student and research assistant). As a result of his work, he published a paper in the Journal Physical Review E (https://journals.aps.org/pre/abstract/10.1103/PhysRevE.105.064301), and has two more under review with himself as first author. In 2021 he enrolled in a master's degree in Cognitive Neuroscience and joined the Center for Cognitive and Computational Neuroscience (Complutense University of Madrid). There, he worked as research staff for a year in the European project EBRAINS, and is now conducting his PhD with a La Caixa fellowship (grand code: B006205). Collaborating with Harvard’s Sepulcre lab, his thesis aims to assess the effectiveness of non-invasive brain stimulation to enhance the effects of cognitive training in preclinical populations of Alzheimer’s disease. Furthermore, he collaborates with the Neural Circuits and Computations Unit at The RIKEN Center for Brain Science on a project focused on clarifying the onset of epileptic seizures within the hippocampal formation.

Angela Tam is a senior scientist at Perceiv AI, a precision medicine company that forecasts disease progression. She completed a PhD in neuroscience at McGill University and a postdoctoral fellowship at the National University of Singapore. Her research interests include using neuroimaging and machine learning to further our understanding of age-related neurodegenerative diseases in order to develop clinical trial enrichment strategies and clinical decision support tools.

Name: Koichi TANAKA Institution: Mass Spectrometry Research Laboratory, Shimadzu Corporation Position: Executive Research Fellow / General Manager Degree 1983. 3 B.A., Engineering, Tohoku University Experience 1983. 4 Central Research Laboratory, Shimadzu Corporation. 1992. 1 KRATOS Group PLC. in UK 1997. 4 Shimadzu Research Laboratory (Europe) Ltd. in UK 1999.12 KRATOS Group PLC. in UK 2002.11 Fellow, Shimadzu Corporation 2003. 1 General Manager, Mass Spectrometry Research Lab., Shimadzu Corporation 2012. 6 Senior Fellow, Shimadzu Corporation 2020. 4 Executive Research Fellow, Shimadzu Corporation Honors & Awards 1989. 5 Encouragement Award from the Mass Spectroscopy Society of Japan 2002.11 Order of Cultural Merit Award 2002.12 Nobel Prize in Chemistry Research fields Development of tools and methods for analysis of protein and carbohydrate structure

Dr. Rudolph Tanzi is the Director of the Genetics and Aging Research Unit, Co-Director of the McCance Center for Brain Health, Co-Director of the MassGeneral Institute for Neurodegenerative Disease, and Vice-Chair of Neurology at Massachusetts General Hospital. He is also the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School. Dr. Tanzi co-discovered the first Alzheimer’s disease (AD) genes including the amyloid gene (APP) and the first AD neuroinflammation gene, CD33. He also discovered the Wilson’s disease gene and helped discover the first ALS gene, SOD1. Dr. Tanzi’s lab first used human stem cells to create mini-human brain organoid models of AD, which have made drug discovery exponentially faster and cheaper. He has used these models to develop novel AD drugs including gamma secretase modulators that lower amyloid production and are being prepared for clinical trials. Dr. Tanzi has helped create numerous biotech companies, including Amylyx, which developed the newly approved ALS drug, Relyvrio. He has published over 675 papers (>150,000 citations), received numerous awards, including the Metropolitan Life Award, Potamkin Prize, and Smithsonian American Ingenuity Award, is a member of the National Academy of Medicine, and has been included on the list of the TIME100 Most Influential People in the World. Dr. Tanzi is also a New York Times bestselling author of Decoding Darkness, Super Brain, Super Genes, and The Healing Self,

Dr. Julia TCW is an Assistant Professor at Boston University and a Director of the Laboratory of Human Induced Pluripotent Stem Cell Therapeutics. She received Ph.D. and A.M. in the Department of Molecular and Cellular Biology from Harvard University and research studies in iPSC reprogramming in the Department of Stem Cell and Regenerative Biology. She then perused her postdoctoral research in the Department of Neuroscience, Ronald M. Loeb Center for Alzheimer’s Disease at Mount Sinai, New York. Her research focuses on studying Alzheimer’s disease genetics and functional genomics especially APOE using computational approaches and human iPSC models and developing therapeutic modalities. She achieved Druckenmiller Fellowship award from New York Stem Cell Foundation, K and R awards from NIH-NIA, Alzheimer's Disease Research Award from BrightFocus Foundation and selected as 2022 Toffler Scholar from Karen Toffler Charitable Trust.

Dr Leffa holds an MD-PhD from the Federal University of Rio Grande do Sul, Brazil. Throughout the course of their doctoral studies, Dr Leffa specialized in neuromodulation techniques for ADHD. Currently, as a psychiatry resident at the University of Pittsburgh Medical Center, Dr Leffa is actively engaged in researching the intricate link between ADHD and cognitive decline, with a specific emphasis on the development of Alzheimer's disease. Dr. Leffa's comprehensive approach includes conducting epidemiological studies, exploring genetic factors, and leading clinical trials.